BOZEN , Italy, June 29. Health-Robotics today announced that it has signed an exclusive 5-year strategic partnership with Grifols S.A., the leading Pharmacy Automation provider in Spain, Portugal, and South America. Grifols desires to safely, accurately, and cost-effectively automate the preparation of non-hazardous IV Admixtures with Health Robotics’ i.v.STATION Robot. As part of this strategic partnership, Grifols will take delivery of 120 i.v.STATION Robots between now and December 2014 for deployment in Spain, Portugal, Chile, Brazil, Argentina, Uruguay, Paraguay, Peru, Ecuador, Bolivia, Venezuela, Colombia, Honduras, Costa Rica, Panama, El Salvador, Nicaragua, Guatemala, Surinam, Guyana, Belize, and French Guyana.
“We are very pleased to have been chosen by Health Robotics as their exclusive i.v.STATION partner in our core markets. i.v.STATION represents an ideal complement to other oral medication automation products such as BlisPack, Pyxis’ MedStation, Kardex Carroussels, and to our systems for IV preparation as Misterium clean rooms or the Grifill sterile compounding device sector in which we hold a commanding lead in Spain, Portugal and South America with over 200 hospitals utilizing our Pharmacy Automation technology.
Grifols believes that i.v.STATION has the real potential to revolutionize Pharmacy Automation for IVs patient doses globally,” stated Ramon Riera, Executive Member of the Board of Directors and Vice President of Marketing and Sales, Grifols.
i.v.STATION represents a revolutionary approach in the quest for safe, accurate, efficient, cost effective, and ready-to-administer IV Admixtures. Constructed around a scalable, distributed, and fail-safe architecture, i.v.STATION offers unprecedented final container flexibility, life-critical patient safety, and robotic precision and performance. i.v.STATION may be deployed in a variety of locations, including central and satellite pharmacies and direct patient care areas, due to its self-contained form, ISO Class 5 environment, and small “foot print”. Pharmacies may, for the first time, choose a robotic configuration that suits their needs, rather than being forced into the dated alternative of “one-size-fits-all, million-dollar-plus” robots designed 10 years ago. Whether a Pharmacy chooses a single or multiple i.v.STATION configurations, it will benefit from fully automated compounding while producing its ready-to-administer IV doses in a variety of syringe, bag, vial, and tamper-evident caps from diverse medical suppliers.
“Grifols is everything we look for in a strategic partner for Health Robotics: company stability, world-class service infrastructure, well-developed marketing channels, and experience in IV therapy, clinical nutrition, and pharmacy automation.
I was extremely impressed to see their manufacturing and biomedical expertise and the large footprint they have achieved with over 100 hospitals utilizing Pyxis MedStation technologies in their core markets. I hope this is just the beginning of a long-term partnership expanding into manufacturing and other unexplored fields in Robotics pharmacy automation such as total parenteral nutrition,” stated Werner Rainer, Health Robotics’ CEO.
About Health Robotics:
Health Robotics is the global leading supplier of life-critical intravenous medication preparation, compounding, and dispensing Robots, with fifty times more units sold that all of its competitors combined, and providing healthcare facilities in four continents with robotics technology and software automation solutions. The world-leading solutions CytoCare (hazardous IVs), i.v.STATION (non-hazardous IVs), and the current development of TPNstation (parenteral nutrition) have and will greatly contribute to ease global hospitals’ and clinics’ growing pressures to improve patient safety through the effective and efficient production of sterile, accurate, and ready-to-administer IVs, to eliminate life-threatening drug-exchange errors, to decrease other medication errors and contamination risks, and to work more efficiently, increase throughput, reduce waste, and contain costs.
Grifols S.A. is a Spain-based company engaged in the healthcare sector and is listed on Ibex-35 stock market. Grifols is involved in the research, development, manufacturing and marketing of plasma derivates, IV therapy solutions, enteral and parenteral nutrition, diagnostic systems, pharmacy automation, and medical materials and devices. Founded in 1940, Grifols currently operates in 90 countries with more than 6.000 employees, 26 subsidiaries with combined gross revenues over euro 800 million, and a euro 3 billion market capitalization.
For additional information, please contact:
Gaspar G. DeViedma
Altmanstrasse 9A, Bozen, Sud-Tyrol, I-39100
Gabinete de Prensa Grifols
Europe: +34-91-311-9289 / +91-221-7448 / +34-659-572-185